These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 31517534)
1. Ensemble docking-based virtual screening toward identifying inhibitors against Wee1 kinase. Li Y; Wu DM; Kong LM; Zhang S; Du H; Sun W; Zhang L; Li Y; Zuo Z Future Med Chem; 2019 Aug; 11(15):1889-1906. PubMed ID: 31517534 [No Abstract] [Full Text] [Related]
2. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors. Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133 [TBL] [Abstract][Full Text] [Related]
3. Broadening the scope of WEE1 inhibitors: identifying novel drug candidates via computational approaches and drug repurposing. Chandrasekaran J; Sivakumaresan Y; Shankar K; Dickson M; Laya Saravana Kumar S; Ramanathan L; Ahmad I; Patel H J Biomol Struct Dyn; 2024 Nov; 42(18):9337-9347. PubMed ID: 37632319 [TBL] [Abstract][Full Text] [Related]
4. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. Matheson CJ; Casalvieri KA; Backos DS; Reigan P ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation. Li Y; Pu Y; Liu H; Zhang L; Liu X; Li Y; Zuo Z J Comput Aided Mol Des; 2018 Sep; 32(9):901-915. PubMed ID: 30182144 [TBL] [Abstract][Full Text] [Related]
6. Development and Characterization of a Wee1 Kinase Degrader. Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695 [TBL] [Abstract][Full Text] [Related]
7. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines. Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690 [TBL] [Abstract][Full Text] [Related]
9. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892 [TBL] [Abstract][Full Text] [Related]
10. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782 [TBL] [Abstract][Full Text] [Related]
11. WEE1 inhibition enhances sensitivity to hypoxia/reoxygenation in HeLa cells. Goto T; Homma H; Kaida A; Miura M J Radiat Res; 2019 Oct; 60(5):709-713. PubMed ID: 31347653 [TBL] [Abstract][Full Text] [Related]
12. Wee1 kinase as a target for cancer therapy. Do K; Doroshow JH; Kummar S Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427 [TBL] [Abstract][Full Text] [Related]
13. Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors. Zhu JY; Cuellar RA; Berndt N; Lee HE; Olesen SH; Martin MP; Jensen JT; Georg GI; Schönbrunn E J Med Chem; 2017 Sep; 60(18):7863-7875. PubMed ID: 28792760 [TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the Iannuzzi CA; Indovina P; Forte IM; Di Somma S; Malfitano AM; Bruno M; Portella G; Pentimalli F; Giordano A Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33020398 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of Wee1 kinase degraders. Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799 [TBL] [Abstract][Full Text] [Related]
16. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Geenen JJJ; Schellens JHM Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503 [TBL] [Abstract][Full Text] [Related]
17. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798 [TBL] [Abstract][Full Text] [Related]
19. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells. Li C; Shen Q; Zhang P; Wang T; Liu W; Li R; Ma X; Zeng X; Yin Y; Tao K J Exp Clin Cancer Res; 2021 Oct; 40(1):315. PubMed ID: 34625086 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]